Related Experiment Video
Updated: Aug 7, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Bacterial derived proteoliposome for allergy vaccines
Miriam Lastre1, Oliver Pérez, Alexis Labrada
1Immunology Department, Finlay Institute, P.O. Box 16017, Havana, Cuba. mlastre@finlay.edu.cu
Vaccine
|July 11, 2006
Summary
Proteoliposomes (PL) show potential as adjuvants in anti-allergic vaccines by shifting immune responses towards a Th1 pattern. This approach effectively reduced allergic indicators in mice, suggesting promise for vaccine development.
Area of Science:
- Immunology
- Vaccinology
- Allergy Research
Background:
- Developing effective anti-allergic vaccines requires potent adjuvants to induce specific immune responses.
- Proteoliposomes (PL) are being investigated as potential adjuvants due to their ability to modulate immune cell activity.
Purpose of the Study:
- To evaluate the potential of Proteoliposomes (PL) as adjuvants in anti-allergic vaccines.
- To assess the immunomodulatory effects of PL combined with Dermatophagoides siboney (Ds) allergens in a murine model.
Main Methods:
- Purified Dermatophagoides siboney (Ds) allergens were formulated with PL and adsorbed onto Al(OH)3.
- Immunological responses, including Th1/Th2 profiles, cytokine production, antibody subclasses (IgG2a), and delayed-type hypersensitivity (DTH), were measured in mice.
- Specific IgE and IL-5 levels were also assessed.
Main Results:
- The anti-Ds response was shifted towards a Th1 pattern, evidenced by increased IgG2a and gamma-interferon (IFN) production.
- A positive DTH response was observed.
- A significant decrease in specific IgE and IL-5, key indicators of allergic reactions, was noted.
- Lower doses of PL were found to be more effective than higher doses.
Conclusions:
- Proteoliposomes (PL) demonstrate significant potential as adjuvants for anti-allergic vaccines.
- PL effectively modulate the immune response to allergens, promoting a Th1-biased immunity and reducing allergic markers.
- Further research into PL-based vaccine formulations is warranted for the treatment of allergies.
Related Concept Videos
00:42Cross-reactivity
Overview
02:06Allergic Reactions
Overview
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...